文献速递心律失常

脉冲场消融治疗心房颤动:PULSED AF 关键性试验

Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial.
PubMed 文献 · Circulation · 2023-03-06

PULSED AF 是一项前瞻性、全球、多中心、非随机、配对单臂研究,纳入阵发性(n=150)和持续性(n=150)症状性房颤患者,这些患者对 I 类或 III 类抗心律失常药物无效,接受脉冲场消融治疗。1 年时,阵发性房颤患者无急性手术失败、心律失常复发或抗心律失常药物升级的比例为 66.2%(95% CI 57.9-73.2),持续性房颤患者为 55.1%(95% CI 46.7-62.7)。主要安全性终点(无严重手术和器械相关不良事件)在阵发性和持续性房颤队列中均仅 1 例患者发生(0.7%;95% CI 0.1-4.6)。

要点

  • 脉冲场消融在阵发性房颤1年有效率为66.2%,持续性房颤为55.1%。
  • 主要安全性终点事件率低,两个队列均为0.7%。
  • 该非热消融能量在1年内有效性与其他消融技术一致。

核心结论

  • PULSED AF 表明脉冲场消融治疗房颤的主要安全性不良事件率低(0.7%),且有效性与其他成熟消融技术一致。

研究设计与样本

  • 前瞻性、全球、多中心、非随机、配对单臂研究,纳入阵发性房颤(n=150)和持续性房颤(n=150)患者。
  • 患者均为症状性房颤且对 I 类或 III 类抗心律失常药物无效。
  • 所有患者使用每周和症状性经电话监测、3、6、12 个月心电图以及 6、12 个月 24 小时动态心电图监测随访 1 年。

主要发现

  • 阵发性房颤患者 1 年主要有效性终点(无急性手术失败、心律失常复发或抗心律失常药物升级的复合终点,排除 3 个月空白期)成功率为 66.2%(95% CI 57.9-73.2)。
  • 持续性房颤患者 1 年主要有效性终点成功率为 55.1%(95% CI 46.7-62.7)。
  • 主要安全性终点(无严重手术和器械相关不良事件)在阵发性和持续性房颤队列中均发生于 1 例患者(0.7%;95% CI 0.1-4.6)。

临床怎么用

  • 对于对 I 类或 III 类抗心律失常药物无效的症状性阵发性和持续性房颤患者,脉冲场消融是一种有效且安全性良好的消融选择。

局限性

  • 本研究为非随机单臂设计,未设传统热消融对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulsed field ablation uses electrical pulses to cause nonthermal irreversible electroporation and induce cardiac cell death. Pulsed field ablation may have effectiveness comparable to traditional catheter ablation while preventing thermally mediated complications. METHODS: The PULSED AF pivotal study (Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF) was a prospective, global, multicenter, nonrandomized, paired single-arm study in which patients with paroxysmal (n=150) or persistent (n=150) symptomatic atrial fibrillation (AF) refractory to class I or III antiarrhythmic drugs were treated with pulsed field ablation. All patients were monitored for 1 year using weekly and symptomatic transtelephonic monitoring; 3-, 6-, and 12-month ECGs; and 6- and 12-month 24-hour Holter monitoring. The primary effectiveness end point was freedom from a composite of acute procedural failure, arrhythmia recurrence, or antiarrhythmic escalation through 12 months, excluding a 3-month blanking period to allow recovery from the procedure. The primary safety end point was freedom from a composite of serious procedure- and device-related adverse events. Kaplan-Meier methods were used to evaluate the primary end points. RESULTS: Pulsed field ablation was shown to be effective at 1 year in 66.2% (95% CI, 57.9 to 73.2) of patients with paroxysmal AF and 55.1% (95% CI, 46.7 to 62.7) of patients with persistent AF. The primary safety end point occurred in 1 patient (0.7%; 95% CI, 0.1 to 4.6) in both the paroxysmal and persistent AF cohorts. CONCLUSIONS: PULSED AF demonstrated a low rate of primary safety adverse events (0.7%) and provided effectiveness consistent with established ablation technologies using a novel irreversible electroporation energy to treat patients with AF. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04198701.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Verma A, Haines DE, Boersma LV, et al. Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. Circulation. 2023. PMID: 36877118. doi:10.1161/CIRCULATIONAHA.123.063988

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。